Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 51ºÚÁϳԹÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Quantification of the haemagglutinin in monovalent influenza vaccines by a latex agglutination assay (LAA) as an alternative to the single radial immunodiffusion (SRID) assay
To formulate inactivated influenza vaccines, the concentration of haemagglutinin (HA) must be accurately determined. The
standard test currently used to measure HA in influenza vaccines is the single radial immunodiffusion (SRID) assay. The SRID
assay is a cumbersome technique presenting a number of drawbacks such as low sensitivity and interference by some adjuvants. We
developed a very simple, sensitive and rapid alternative HA assay using latex agglutination. The LAA uses the Spherotest�® technology,
which is based on the agglutination of HA-specific immunoglobulin-coated latex beads, which bind to the HA. The amount of HA
in a sample can then be calculated from the level of bead agglutination by a simple absorbance measurement. A standard curve is
generated using serially diluted HA reference protein. The results show that for monovalent A/H5N1 and A/H1N1 vaccines, the
LAA demonstrated equivalent linearity, accuracy and precision as compared to the SRID assay. Moreover, unlike the SRID assay,
LAA enables HA quantification in AlOOH-adjuvanted vaccines and in emulsion-based adjuvanted vaccines without interference.
In addition, LAA was found to be more simple, rapid and sensitive than SRID. In conclusion, LAA may be useful to rapidly and
accurately quantify the influenza HA protein in monovalent vaccines, especially in those formulated with low amounts of HA in the
presence of an adjuvant.
Biography
Sophie Buffin joined the Research department of Sanofi Pasteur in 2005 with a Master’s degree. She is currently a Ph.D. student at the University of Lyon.